About Us
About Taiwan Exosome Co., Ltd.
Taiwan Exosome Co., Ltd. was established in 2021, dedicated to the horizontal and vertical development of novel drugs using human, animal, and plant exosomes. The company conducts in-depth scientific research and development in exosome industry technology, utilizing the most professional knowledge, equipment, and advanced technology as the foundation. It focuses on developing treatments for difficult-to-treat diseases, including autoimmune diseases and sarcopenia. Taiwan Exosome also aims to establish a "Pharmaceutical-Grade Exosome Industry Technology Platform," which includes modules for exosome separation, purification, identification, and mass production technology, making it a leader across the upstream, midstream, and downstream regenerative medical industry chain.
Research Team
Our research team is led by Dr. Chuang Yin-Ching, the first person in Taiwan to obtain information on the COVID-19 virus. He is also the former director of Liuying Chi Mei Hospital and a renowned infectious disease expert. He oversees scientific and fundamental medical research and collaborates with Dr. Chen Zhen-Xing who is a leading figure in the medical field, a medical doctor from Johns Hopkins University, and a senior advisor at the WHO South Europe Collaboration Center.
The team also includes researchers from the Liuying Chi Mei Hospital Laboratory, the laboratory of department of Biochemical Science and Technology at National Taiwan University’s College of Life Science, dozens of authoritative medical professionals from around the world (including the United States, Canada, and China), senior scientific experts, and experienced scholars dedicated to advancing research.
